Europe’s CHMP Supports Carvykti T-cell Therapy Approval in EU
Carvykti (ciltacabtagene autoleucel; cilta-cel) has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP), an arm of the…
News
Longer Survival for Black vs White Myeloma Patients With Same Care
Black people with multiple myeloma live longer than white patients with similar disease symptoms when both receive the same new and updated medical treatments,…
Patients Have Higher COVID-19 Risk Even if Fully Vaccinated: US Study
Even if they’re fully vaccinated, multiple myeloma patients still have an increased risk of COVID-19 infection compared with people without cancer, according to a…
RaDaR Serves as Starting Point for Creating Rare Disease Registry
Patient registries are a hot topic of rare disease research and many organizations are taking advantage of this resource by signing up their patient communities…
Sarclisa Extends Survival in RRMM, Long-term Phase 3 Trial Data Shows
The therapy Sarclisa (isatuximab) extended survival by nearly seven months in relapsed/refractory multiple myeloma patients also given Pomalyst (pomalidomide) and dexamethasone as standard…
#RAREis Representation Program Promotes Equity, Diversity
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million…
FDA Places HPN217, Immunotherapy for Advanced Disease, on Fast Track
The U.S. Food and Drug Administration (FDA) has given fast track designation to Harpoon Therapeutics’ HPN217 as a potential immunotherapy for people with relapsed, refractory …
Rare Disease Day Panel Opens Window to Patient Experience
Bionews, the publisher of this website, hosted a virtual panel discussion on Rare Disease Day 2022, taking a deeper dive into what it’s like…
FDA Approves Cilta-cel as Carvykti for Heavily Treated Myeloma
The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) — formerly known as cilta-cel — for certain…
Surge in Telehealth Brings Access, Convenience to Rare Disease Patients
A rare disease puts an economic burden on the patients, families, and caregivers that it affects, and will no doubt be an integral part of…
